Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
VolitionRX ( (VNRX) ) has provided an announcement.
At a special meeting held on March 31, 2026, shareholders of VolitionRx Limited authorized the board to implement a reverse stock split of its common stock, and the board has now set the ratio at one-for-twenty. The move, linked in part to financing arrangements with Lind Global Asset Management XII LLC completed in May 2025 and January 2026, will become effective at 12:01 a.m. ET on April 28, 2026, with shares trading on a split-adjusted basis from market open.
Under the reverse split, every 20 shares of common stock will automatically convert into one share, with no fractional shares issued and any fractions rounded up to the nearest whole share or settled in cash where applicable. The transaction will trigger proportionate adjustments to all outstanding equity incentive awards, warrants, convertible notes, and shares reserved for issuance, reshaping VolitionRx’s capital structure and potentially supporting its compliance and financing objectives.
The most recent analyst rating on (VNRX) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on VolitionRX stock, see the VNRX Stock Forecast page.
Spark’s Take on VNRX Stock
According to Spark, TipRanks’ AI Analyst, VNRX is a Neutral.
The score is held down primarily by weak financial performance (persistent losses, cash burn, and negative equity). The earnings call adds support via improving cost discipline, strong percentage revenue growth, and partnership/scientific momentum, but technical indicators remain mixed and valuation is difficult to assess due to negative earnings.
To see Spark’s full report on VNRX stock, click here.
More about VolitionRX
VolitionRx Limited operates in the life sciences and diagnostics sector, focusing on the development and commercialization of blood-based tests leveraging its proprietary technologies. The company’s common stock is publicly traded, and it uses equity incentives, warrants, and convertible notes as part of its capital and compensation structure.
Average Trading Volume: 11,405,370
Technical Sentiment Signal: Strong Sell
Current Market Cap: $27.1M
See more data about VNRX stock on TipRanks’ Stock Analysis page.